Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Stealth BioTherapeutics Corp (MITO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.3084+0.0012 (+0.39%)
At close: 04:00PM EDT
0.3200 +0.01 (+3.76%)
After hours: 04:55PM EDT
Advertisement

Stealth BioTherapeutics Corp

190 Elgin Avenue
George Town KY1-9005
Cayman Islands

https://www.stealthbt.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Ms. Irene P. McCarthy J.D.Pres ,CEO, Sec. & DirectorN/AN/A1965
Mr. Henry HessChief Legal CounselN/AN/AN/A
Dr. Ben R. Bronstein M.D.Chief Medical OfficerN/AN/A1950
Mr. Brian HotchkissVP of Bus. Devel. & StrategyN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Corporate Governance

Stealth BioTherapeutics Corp’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement